| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5837cc3fe9e05283876fe3a7d7edf545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de094784025e53546f898a3de5a5e393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76f848d9755383c1f9148a3ccefb776d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11c5298388bf5090410400c6e8f51ed1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 |
| filingDate |
2010-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69da3296dfc3a4d788a7fe1f408edafb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb631c127fe4cda0e323e2586e04a22f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aca3480f65fbb86060506a719ed2139f |
| publicationDate |
2011-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2011068953-A3 |
| titleOfInvention |
Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| abstract |
Atoxic Clostridium difficile toxin proteins were expressed in an endotoxin-free Bacillus system top develop a vaccine to reduce incidence and severity of C. difficile infection (CDI). Immunogens evaluated as potential vaccine candidates are mutated toxin A (encoded by TcdA) and toxin B (TcdB), and a rationally designed chimeric protein containing full-length TcdB protein except that the receptor binding domain is replaced with that of TcdA (designated as cTxAB). A small deletion (97 amino acids) in the transmembrane domain was used to reduce or eliminate toxicity. |
| priorityDate |
2009-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |